|
|
|
| Discussion on the medication rule of Professor Feng Ling in treating chronic heart failure based on data mining |
| LI Siming1 CHENG Xiaozhen2 CHEN Xingjuan2 HOU Chengzhi2 WU Yiru2 FENG Ling2 |
1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Cadre Health Care, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
|
|
|
|
Abstract Objective To investigate the medication rule of Professor Feng Ling in the treatment of chronic heart failure. Methods Effective chronic heart failure medical records of Professor Feng Ling’s outpatient department in Guang’anmen Hospital, China Academy of Chinese Medical Sciences from January 2016 to January 2022 were collected. Traditional Chinese medicine inheritance computing platform (V3.0) was used to conduct drug frequency, four nature, five flavours, channel tropism, efficacy, and association rules of prescriptions, and to explore medication rules. Using the “prescription cluster analysis” module, the core prescription was mined by the entropy hierarchical clustering method of complex system. Results A total of 1 151 effective prescriptions were collected, involving 225 kinds of Chinese materia medica. There were ten kinds of Chinese materia medica with frequency≥467, among which Astragali Radix, Santali Albi Lignum, and Mori Cortex had the highest frequency. In the four nature, cold and warm were the main, followed by flat. In the five flavours, sweet and pungent were the main, followed by bitter. In the channel tropism, spleen, lung, and heart channels were the main. The efficacy of the drug was divided into 17 categories, such as regulating qi, tonifying deficiency, diuresis and diffusing dampness, promoting blood circulation for removing blood stasis, resolving phlegm and relieving cough and asthma, and so on. Association rule analysis obtained 18 associated couplet medicines. Eight core prescription were obtained by high-frequency drug cluster analysis. The core presicripton were composed of Astragali Radix, Mori Cortex, Arecae Pericarpium, Poria, Polyporus, Salviae Miltiorrhizae Radix Et Rhizoma, Santali Albi Lignum, and Aucklandiae Radix. Conclusion Professor Feng Ling’s medication approach for chronic heart failure involves treating qi deficiency, blood stasis, and water stasis as the core pathogenesis. The treatment of invigorating spleen and benefiting qi, activating blood circulation to dissipate blood stasis, inducing diuresis for removing edema as the method. “Spleen, lung and heart” are treated simultaneously; “sweet, pungent, and bitter” are used all at once.
|
|
|
|
|
|
[1] 罗烨，欧阳昆富，陈延军.沙库巴曲缬沙坦对射血分数降低心力衰竭患者超声、生化、临床方面的短期疗效[J].分子影像学杂志，2020，43（2）：291-295.
[2] Pontremoli R，Borghi C，Perrone Filardi P. Renal protection in chronic heart failure：focus on sacubitril/valsartan [J]. Eur Heart J Cardiovasc Pharmacother，2021，7（5）：445-452.
[3] 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[4] Zhang Y，Zhang J，Butler J，et al. Contemporary epidemiology，management，and outcomes of patients hospitalized for heart failure in China：results from the China Heart Failure（China-HF）Registry [J]. J Card Fail，2017，23（12）：868-875.
[5] 国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组.2020中国心力衰竭医疗质量控制报告[J].中国循环杂志，2021，36（3）：221-238.
[6] McDonagh TA，Metra M，Adamo M，et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur Heart J，2021，42（36）：3599-3726.
[7] 郭城楠.慢性心力衰竭药物治疗临床研究进展[J].天津药学，2022，34（4）：64-69.
[8] 程晓振，胡木，冯玲.冯玲基于“三焦”论治慢性心力衰竭[J].辽宁中医杂志，2021，48（12）：39-41.
[9] 陈兴娟，陈韵卓，胡影，等.利水强心方改善慢性心衰患者心功能的临床研究[J].中国临床医生杂志，2022，50（2）：148-150.
[10] Ho KK，Pinsky JL，Kannel WB，et al. The epidemiology of heart failure：the Framingham Study [J]. J Am Coll Cardiol，1993，22（4 Suppl A）：6A-13A.
[11] 戴闺柱.慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志，2002，30（1）：7-23.
[12] 郑筱萸.中药新药治疗心力衰竭的临床研究指导原则[M].北京：中国医药科技出版社，2002：77-84.
[13] 国家药典委员会.中华人民共和国药典[M].一部.北京：中国医药科技出版社，2020.
[14] 盖晓丽.从三焦气化理论探讨针灸治疗代谢综合征[J].江苏中医药，2020，52（8）：11-13.
[15] 王玉敏.黄芪总提物及黄芪有效成分治疗心衰的心肌力能学机制研究[D].北京：中国中医科学院，2012.
[16] 丁倩云，马双成，许风国，等.桑白皮的化学成分、药理及质量控制研究进展[J].药物分析杂志，2021，41（7）：1114-1124.
[17] 吴科锐，韩凌.羧甲基茯苓多糖药理作用研究进展[J].中药材，2017，40（3）：744-747.
[18] 王天媛，张飞飞，任跃英，等.猪苓化学成分及药理作用研究进展[J].上海中医药杂志，2017，51（4）：109-112.
[19] 郑加梅，尚明越，王嘉乐，等.木香的化学成分、药理作用、临床应用研究进展及质量标志物预测[J].中草药，2022，53（13）：4198-4213.
[20] 陈士铎.本草新编[M].北京：中国医药科技出版社，2011： 28.
[21] 黄宫绣.本草求真[M].上海：上海科学技术出版社，1979：153.
[22] 李亚洲，胡业彬，王建勋，等.茯苓温肾胶囊对慢性心力衰竭患者细胞因子的影响[J].中医药临床杂志，2016， 28（8）：1114-1116.
[23] 赵宇辉，唐丹丹，陈丹倩，等.利尿药茯苓，茯苓皮，猪苓和泽泻的化学成分及其利尿作用机制研究进展[J].中国药理学与毒理学杂志，2014，28（4）：594-599.
[24] 叶天士.本草经解[M].上海：上海卫生出版社，1958. |
|
|
|
